Laddar populära aktier...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events...
AAC Clyde Space (AAC) remains an interesting avenue into the fast-growing low Earth orbital space se...
Solid Q3 report, adj. EBITA +9% y-o-y Price hikes in Q4 to benefit margins '25e-'26e EBITA +1%, 12x-...
Group net sales was EUR 31.2m in Q3 (Nordea est. EUR 31.
Investors House reported Q3 revenues of EUR 2.4m, 10% below our EUR 2.
Redeye makes minor estimate changes following Arise’s Q3 report, due Thursday last week.
Redeye provides an update following SenzaGen’s Q3 2024 report.
Redeye comments on Lifeclean’s order from a defense authority in a European country.
Refine Group (”Refine”, ”koncernen” eller ”bolaget”) publicerade den 8 november 2024 bolagets delårs...
Sales -9% (-16% ex. M&A), EBITA 5.7% (8.8%), but vs.
Redeye provides its initial comments on Nanologica's Q3 report, which showed softer-than-expected sa...
Q3 slightly slower than expected, partly due to discontinued product We cut '24e-'26e adj.
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, bu...
We leave estimates relatively unchanged after Q3...
After the recent rights issue, Ascelia has SEK 95.
